Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 48 citing articles:

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Joe‐Elie Salem, Marie Bretagne, Baptiste Abbar, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1100-1115
Open Access | Times Cited: 112
Cardiovascular complications of immune checkpoint inhibitors for cancer
Franck Thuny, Jarushka Naidoo, Tomas G. Neilan
European Heart Journal (2022) Vol. 43, Iss. 42, pp. 4458-4468
Open Access | Times Cited: 74
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova La
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1243-1243
Open Access | Times Cited: 30
Toxicity in the era of immune checkpoint inhibitor therapy
Synat Keam, Naimah Turner, Fernanda G. Kugeratski, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Corticosteroid-resistant immune-related adverse events: a systematic review
Eveline Daetwyler, Till Wallrabenstein, David König, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 1, pp. e007409-e007409
Open Access | Times Cited: 11
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Amir Munir, Alan Gutierrez, Juan Qin, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 8, pp. 540-553
Closed Access | Times Cited: 8
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Yuhsin Vivian Huang, Yin Sun, Harrison Chou, et al.
Circulation Research (2025)
Closed Access | Times Cited: 1
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
Javid J. Moslehi, Joe‐Elie Salem
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 704-707
Open Access | Times Cited: 29
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1231-1248
Open Access | Times Cited: 19
The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future
Douglas L. Mann
Circulation Research (2024) Vol. 134, Iss. 12, pp. 1663-1680
Closed Access | Times Cited: 6
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C. Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Distinct immune-effector and metabolic profile of CD8+T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors
Karolina Benesova, Franziska V. Kraus, Rui A. Carvalho, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1730-1741
Open Access | Times Cited: 20
A Novel Therapeutic Approach using CXCR3 Blockade to Treat Immune Checkpoint Inhibitor-mediated Myocarditis
Yuhsin Vivian Huang, Daniel Lee, Yin Sun, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Ying Wang, Carolin Ertl, Christina Schmitt, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 4
TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis
Xiaohang Liu, Wei Wu, Ligang Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
The role of immune checkpoints in cardiovascular disease
Laura I. Yousif, Anniek A. Tanja, Rudolf A. de Boer, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 17
The oft-overlooked cardiovascular complications of inflammatory bowel disease
Sara Massironi, Giacomo Mulinacci, Camilla Gallo, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 4, pp. 375-391
Closed Access | Times Cited: 9
Immune Checkpoint Inhibitor-Associated Myocarditis: From Pathophysiology to Rechallenge of Therapy – a Narrative Review
Andrea Tedeschi, Massimiliano Camilli, Enrico Ammirati, et al.
Future Cardiology (2023) Vol. 19, Iss. 2, pp. 91-103
Closed Access | Times Cited: 9
Tofacitinib Is an Effective Treatment for Refractory Scleromyositis Associated With Anti-PM/Scl
Jorge Álvarez Troncoso, A. Nuño‐González, Elena Martínez Robles, et al.
Cureus (2023)
Open Access | Times Cited: 7
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities
Judith L. McKenzie, E. Sneath, Andrew Trinh, et al.
Immuno-Oncology Technology (2024) Vol. 21, pp. 100704-100704
Open Access | Times Cited: 2
Protective effect of low‐intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4+ T-cell differentiation
Shuai Fu, Zihong Guo, Xiangli Xu, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 1
Open Access | Times Cited: 2
Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity
John R. Power, Charles Dolladille, Adriel Procureur, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
Qian Xing, Zhongwei Zhang, Biao Zhu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
Omoruyi Credit Irabor, Nicolas G. Nelson, Yash Shah, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
Yen‐Chou Chen, Muhammad Jaffer, Lylybell Zhou, et al.
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top